LabConnect Selects Deloitte to Streamline Financial and Business Operations

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

JOHNSON CITY, Tenn., June 12, 2025 /PRNewswire/ — LabConnect, a leading provider of global central laboratory and support services for clinical trials, has selected Microsoft Dynamics 365 Finance and Supply Chain, and also engaged Deloitte to transform its enterprise resource planning (ERP) platform. This initiative is designed to streamline LabConnect’s financial and business operations while enhancing financial reporting management in line with the company’s long-term growth strategy.

This project marks a significant step forward in LabConnect’s plan to modernize workflows and reduce reliance on manual processes. By automating key financial and operational functions, LabConnect will increase efficiency and position itself for rapid global scaling.

“As we continue to expand our global footprint, this ERP modernization will enable LabConnect to better serve our clients with more responsive and efficient solutions,” said David Rynders, Vice President, Global Corporate Controller. “LabConnect’s partnership with Deloitte for the implementation of Microsoft Dynamics 365 Finance and Supply Chain strengthens our ability to deliver seamless, efficient, and scalable solutions to our customers around the world. By leveraging Deloitte’s global expertise and industry-leading solutions, we ensure faster, more streamlined operations that enhance service reliability and responsiveness.”

The upgraded ERP system will also deliver significant value and efficiency for LabConnect’s clients.

  • Enhanced automation in finance and supply chain processes will accelerate invoicing, improve kit turnaround times, and increase accuracy across procurement and manufacturing.
  • Advanced Materials Requirements Planning (MRP) capabilities will strengthen the company’s ability to source unique products efficiently, improving trial support logistics.
  • Integrated data systems will deliver more accurate and timely reporting and better visibility into shipping and material tracking.

This transformation reinforces LabConnect’s strategic commitment to operational excellence and positions the company to meet the evolving needs of the global clinical trial landscape.

About LabConnect
LabConnect is the world’s most agile central laboratory solutions partner, providing technology-driven, customized, orchestrated, and scalable support services for clinical trials of all sizes and complexity. With over 20 years experience and 2,000+ clinical studies across 93 countries, LabConnect is the trusted partner for biotechnology, pharmaceutical, and clinical research organizations.

With modern operations and strategic alliances with world-leading laboratories, LabConnect is uniquely positioned to provide access to the latest innovation and automation. LabConnect delivers exceptional service with a comprehensive suite of central laboratory solutions including custom lab kits, advanced sample tracking and integrated logistics, global standardized sample processing, industry-leading testing menu of 20,000+ validated assays, worldwide support for radiopharmaceuticals, and next-generation biorepository.

LabConnect scientific experts support pre-clinical and clinical studies with scientific project management, bioanalytical and biospecimen management, biomarker strategy and logistics solutions. LabConnect excels at data management, integrating complex datasets from diverse sources into a single, cohesive, submission-ready dataset.

Follow LabConnect on LinkedIn
Learn more at www.labconnect.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/labconnect-selects-deloitte-to-streamline-financial-and-business-operations-302480415.html

SOURCE LabConnect

Staff

Recent Posts

Epic UGM 2025 Survival Guide: Insider Tips for Vendors, Storytellers, and Market Watchers

Black Book Research Marks Its 12th Year on the Ground in Verona with Independent, Vendor-Agnostic…

15 hours ago

rYojbaba Co., Ltd. Announces Closing of $5 Million Initial Public Offering of Japanese Common Shares

FUKUOKA, Japan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or…

18 hours ago

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug…

18 hours ago

BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No WarrantsLos Angeles, CA, Aug.…

18 hours ago

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

CRANBERRY TOWNSHIP, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Jabez Biosciences, Inc., a clinical-stage biopharmaceutical…

18 hours ago